Written by Jacob Bakshi
Jacob Bakshi
Senior Market Strategist
Trading CFDs and options has been my playground for years, and I love helping others understand these powerful tools and what makes the financial world tick. My work mostly focuses on giving traders the confidence to make informed decisions with unbiased reviews into platforms that prioritize fair pricing, advanced tools, and reliable execution because In fast-moving markets, every detail matters. I have a background in market analysis and risk management, and I’m always on the lookout for brokers that offer the right tools for serious traders. using our CLEAR™ Methodology The CLEAR™ Score (Credibility, Leverage, Execution, Accessibility, Regulation) is our proprietary ranking system. The CLEAR™ Score provides you with the most accurate and transparent broker ranking after evaluating all the key factors that are crucial for trading success. .
Last fact check on July 1, 2025 by
Shaun David
Shaun David
Regulation • Trading Algorithms • Market Analysis
I’m extremely passionate about the financial markets and working with innovative technology that makes trading better and safer. Since joining the CleaRank team, my primary role is working with real-time broker performance data using the CLEAR™ technology and broker evaluation methodology. I investigate brokers by testing their platforms and uncovering hidden risks and costs. My end goal is to level the playing field for traders and With an extensive background in market analysis and algorithmic trading, I’m qualified to find what matters most to traders.
How UnitedHealth’s 5-Year Low Set Up a Monster Buy Opportunity
If you take a quick glance at the markets, you might think the healthcare sector caught a virus.
UnitedHealth Group ($UNH), the largest health insurer in America, a market titan, and once a bulletproof stock, just plunged to a five-year low. Shares fell more than 50% from their 2024 peak and briefly touched $270 before bouncing. It’s been one of the sharpest and fastest corrections in the company’s history.
So, what happened?
A sudden CEO exit. A pulled earnings forecast. A DOJ probe swirling around Medicare Advantage billing. And to top it off, political attacks on UnitedHealth’s highly profitable OptumRx unit, part of a broader war on PBMs
The headlines look ugly. But under the surface?
“This has all the fingerprints of a behavioral panic, not a fundamental collapse,” says Shaun David, Co-Founder of CleaRank. “The setup for long-term investors is probably the best we’ve seen since the COVID lows.”
Snapshot: Why We’re Bullish on UNH
- UNH is still America’s largest health insurer and a tech-enabled care leader
- Stock is trading at 11× forward earnings, lowest multiple in a decade
- Dividend yield is at 2.9%, the highest since 2011
- Optum and Medicare Advantage still deliver double-digit revenue growth
- 22 out of 27 analysts still rate it a Buy or Strong Buy
- DOJ probe has no formal notification; political pressure likely transient
- Long-term performance? UNH has crushed the S&P 500 for 20+ years
Let’s Talk Numbers
Metric | $UNH |
|---|---|
Current Price | $315.66 |
Market Cap | $287B |
52-Week Range | $248.88 to $630.73 |
Dividend Yield | 2.9% |
Forward P/E | 11x |
Avg. Daily Volume | 12.3M shares |
Q1 Revenue | $109.6B |
Earnings Misses (15 yrs) | 1 |
Analysts Ratings | 22 Buy, 4 Hold, 1 Sell |
The Headlines That Spooked the Market
First, the guidance was yanked. UnitedHealth had previously forecast 2025 earnings between $26.00 to $26.50 per share. But citing higher-than-expected costs in Medicare Advantage and a shift in Optum patient profiles, they pulled the plug. That alone would’ve dinged the stock.
But then came the one-two punch.
CEO Andrew Witty unexpectedly stepped down, citing personal reasons. The company quickly reinstated former CEO Stephen Hemsley, a steady hand, but the timing rattled Wall Street.
And just a day later, whispers of a DOJ investigation into Medicare billing exploded. UnitedHealth firmly denied any formal notice, but the damage was done and the stock tanked fast.
“When it rains in a bull market, no one cares,” Shaun David says. “But when it rains during rotation season and a leadership shakeup, investors bring umbrellas and bail.”
The Business Is Still Solid
The market may be panicking, but the machine hasn’t stopped.
UnitedHealth still generated over $109 billion in quarterly revenue, with Optum alone contributing nearly $55 billion. OptumRx, despite being targeted politically, accounted for over $13.9 billion in Q1 revenue and 16% of company-wide earnings.
“This isn’t some speculative biotech,” Shaun says. “UNH is printing billions in cash, raising dividends, and still gaining members.”
Its vertical integration, paired insurance with PBM, analytics, virtual care, and physician groups, remains unmatched in scale. Even amid noise, UNH is on track for a 2026 growth rebound as it rebalances care costs.
So Why Is Everyone Running?
Because that’s what people do when headlines scream “DOJ” and “CEO quits” on the same day.
But the selling is behavioral, not structural. This is a market that’s punished every whiff of political risk. It dumped Meta on privacy probes. It punished JPMorgan over regulation. And now? It’s nuking UNH over a rumor and a reshuffle.
“Liquidity and sentiment drive stocks in the short term,” Shaun says. “But earnings and scale always win long term. UNH has both.”
Add to that the fact that UNH was a mega-cap Dow component, and indexers had to rebalance aggressively on the way down.
Analyst Views: Still Overwhelmingly Bullish
This may shock you: despite the crash, 22 out of 27 analysts still rate UNH a Buy or Strong Buy. Price targets remain in the $450 to $500 range, which implies nearly 50% upside from current levels.
Even institutions are nibbling. CleaRank’s data shows volume spikes on down days, with long-term accounts increasing exposure.
“They’re not buying the headlines,” Shaun notes. “They’re buying the moat.”
And he’s not alone. Traders who missed UNH in 2020 or 2018 know what this looks like: peak pessimism masking peak potential.
Behavior > Headlines
Let’s take a breath.
Yes, the DOJ is investigating. No, it hasn’t officially charged UNH.
Yes, Witty left suddenly. No, Hemsley isn’t new to the job. He led the company through the 2008 crisis.
Yes, Medicare costs are up. But UNH still dominates the segment and has pricing power heading into 2026.
“This is classic overreaction,” Shaun says. “And that’s exactly when long-term investors make their best buys.”
Insider Buying: CEOs Don’t Spend $25M for Fun
One final detail that most investors missed: the new CEO, Stephen Hemsley, just put his money where his mouth is, buying $25 million worth of UNH stock on May 16, just days after stepping back into the role. He paid an average price of $288.57 per share. CFO John Rex also scooped up $5 million worth. And three UnitedHealth directors followed with additional insider buys totaling $1.6 million.
“Insider buying at this level isn’t a PR move,” says Shaun David. “It’s a signal. Hemsley knows the playbook, he knows the numbers, and he clearly thinks this stock is cheap.”
In a market full of noise, few signals are louder than a CEO betting millions of dollars on his own company.
Our Verdict: This Could Be the Best Entry Point in 5 Years
If you look past the headlines and zoom out a moment, it’s clear that despite UnitedHealth’s stumble, its foundation hasn’t cracked and remains more solid than ever.
It’s still America’s largest insurer. It still owns Optum, one of the most profitable health-tech machines in the world. And it still generates billions in free cash flow, quarter after quarter.
At 11× forward earnings, a 2.9% dividend, and nearly $50 billion in annual Optum revenue, this stock isn’t broken, it’s on sale.
“If you can tune out the noise and zoom out to the fundamentals,” Shaun concludes, “you’re staring at one of the best asymmetric setups in the entire S&P 500 right now.”
FAQ
Why did UnitedHealth drop so much?
A mix of negative headlines: CEO exit, a pulled 2025 outlook, DOJ chatter, and political targeting of OptumRx. But none of these are confirmed red flags. You can read more about the negative headlines impacting UnitedHealth here.
Is this a fundamental or behavioral drop?
Largely behavioral as earnings are still strong and analysts are still bullish. Also valuation is at decade lows. You can read more about the behavioral drop surrounding UnitedHealth here.
Should I worry about the DOJ probe?
The company hasn’t even been formally notified. Until something concrete surfaces, it’s likely an overhang, not a death sentence.
Is OptumRx really in trouble?
It’s under pressure politically, but it’s still profitable and essential to UNH’s long-term strategy.
What’s the upside potential?
If UNH re-rates to its 10-year average P/E of 18× and earnings recover, the stock could easily revisit $500+ in the next 12 to 24 months. You can read more about the UnitedHealth stock forecast here.
Jacob Bakshi
I’m Jacob and I specialize in CFDs, options trading, and market analysis. Over the years, I’ve developed a deep understanding of the risks and rewards that come with trading derivatives and survived enough volatility to know that trading is like skydiving: thrilling, but you’d better trust your parachute (or broker). I use CleaRank’s Methodology to test brokers based on their offerings and ensure traders that visit our site have access to brokers that align perfectly with their trading strategies.